Adventia Pharma's clinical nutrition line, Medical Nutrition and its subsidiary Dieticare form a group to grow in an expanding sector while each maintains its independence.
Clinical nutrition has strong growth prospects. Inevitable market trends, such as the aging population, along with the robust expansion of medical indications, including the care of patients with cancer, dysphagia, or kidney disorders, among others, make it a segment of particular interest with high growth potential.
In this context, Adventia Pharma, a pharmaceutical laboratory specializing in oral diets for clinical nutrition, and ProA Capital, one of the leading private equity fund managers in Spain, have reached an agreement whereby both companies will jointly address the growth of Adventia Pharma and Nutrición Médica (the latter recently acquired by ProA Capital) in the clinical nutrition sector.
The operation, consisting of the creation of a “newly created company” (NewCo) between ProACapital and Adventia Pharma, expands the growth capabilities of the companies in the new partnership.
Medical Nutrition is a laboratory specializing in modules within clinical nutrition, as well as medications in different areas, while Adventia Pharma has a complete vademecum in both oral diets and modules.
Thanks to this complementarity, Adventia Pharma doubles its market coverage in both Spain and Portugal, while completing one of the most comprehensive product portfolios. diversified and market-leading, also gaining greater investment capacity in R&D and innovation in segments yet to be developed.
Founded in 2007, ProA Capital manages different investment programs totaling more than 2 billion euros of capital with a highly selective investment strategy. Adventia Pharma thus becomes a strategic partner of ProA Capital to move forward successfully, as other emblematic companies invested in by the same fund have done in various sectors. Companies that demonstrate ProA Capital's proven investment experience and the positive strategic vision of this operation.